|
- Ibrutinib: Uses, Dosage, Side Effects, Warnings - Drugs. com
Ibrutinib (Imbruvica) is a type of medication called a kinase inhibitor, which is used to treat various blood cancers and also a serious complication of allogeneic stem cell transplants called chronic graft versus host disease (cGVHD)
- Ibrutinib - Wikipedia
Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK)
- Ibrutinib - NCI - National Cancer Institute
Ibrutinib is approved to treat adults with: Chronic lymphocytic leukemia and small lymphocytic lymphoma Chronic lymphocytic leukemia and small lymphocytic lymphoma that has a chromosome change called 17p deletion Waldenström macroglobulinemia (a type of non-Hodgkin lymphoma)
- Imbruvica (ibrutinib) - Uses, Side Effects, and More - WebMD
Imbruvica is a type of medicine called a tyrosine kinase inhibitor It inhibits Bruton’s tyrosine kinase (BTK) on B cells, which are a type of white blood cell When Imbruvica inhibits BTK, it
- Ibrutinib (oral route) - Mayo Clinic
Ibrutinib is used to treat chronic lymphocytic leukemia (CLL) small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL) small lymphocytic leukemia (SLL) in patients with 17p deletion, and Waldenström macroglobulinemia (WM)
- Ibrutinib: Cancer Treatment Uses, Side Effects, Dosage
Ibrutinib is a novel targeted therapy for certain cancers of white blood cells in adults and is also used for the treatment of chronic graft versus host disease in adult and pediatric patients
- Ibrutinib: MedlinePlus Drug Information
Ibrutinib is used to treat adults with chronic lymphocytic leukemia (CLL; a type of cancer that begins in the white blood cells) and small lymphocytic lymphoma (SLL; a type of cancer that begins mostly in the lymph nodes)
- Ibrutinib | Macmillan Cancer Support
Ibrutinib is a targeted therapy drug also known as Imbruvica® It is used to treat some types of lymphoma and leukaemia Learn more about it
|
|
|